Expanded Access to Risankizumab

AbbVie logo

AbbVie

Status

Conditions

Ulcerative Colitis (UC)
Crohn's Disease

Treatments

Drug: Risankizumab

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT03914261
C19-882

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants with Crohn's Disease (CD). This program is designed to provide access to risankizumab, prior to approval by the local regulatory agency, to patients with the highest unmet need and an urgent need for treatment, where risankizumab may prolong survival, prevent occurrence of clinical events associated with significant morbidity and/or mortality, or stabilize a progressive debilitating disease. Availability will depend on a review of the eligibility of the patient and local approval status of risankizumab for CD. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems